Researchers at Memorial Sloan Kettering Cancer Center identified clinically actionable germline mutations in 8.5 percent of about 2,700 unselected lung cancer patients.
The collaboration agreement includes support for development, regulatory submission, and commercialization of tests to guide use of Novartis' drug portfolio.
In a meta-analysis of nearly 70,000 individuals, researchers estimated that low-frequency coding variants contribute about 5 percent of multiple sclerosis risk.
In a meta-analysis of nearly 70,000 individuals, researchers estimated that low-frequency coding variants contribute about 5 percent of multiple sclerosis risk.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
The company has not released data on its method, but describes a circulating tumor DNA approach that has similarities to what other firms are pursuing.
DNA quantification and normalization are required in most genomics workflows, and are usually routinely implemented after the initial nucleic acid purification step. The versatility of the classical absorbance technique still makes it the go-to method for many applications, as the concentration of all DNA and RNA types can be determined using the specific empiric extinction coefficient for each nucleic acid type.
Quantitative PCR (qPCR) is a preferred method for quantification of low amounts of DNA or cDNA due to its high sensitivity, specificity and reproducibility. Consistently high and uniform qPCR efficiencies are crucial for accurate relative quantification of gene expression levels, low copy gene detection or absolute quantification of NGS libraries1.
Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.
In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.
